Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)
- 31 May 2012
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 17 (9-10), 409-412
- https://doi.org/10.1016/j.drudis.2011.12.010
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010The Lancet Oncology, 2011
- Antabuse (disulfiram) as a pilot case of nonprofit drugInternational Journal of Cancer, 2010
- Are Patents Impeding Medical Care and Innovation?PLoS Medicine, 2010
- Predicting new molecular targets for known drugsNature, 2009
- ParomomycinTransactions of the Royal Society of Tropical Medicine and Hygiene, 2009
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion QuestionJNCI Journal of the National Cancer Institute, 2009
- Ni(II), Cu(II), and Zn(II) Diethyldithiocarbamate Complexes Show Various Activities Against the Proteasome in Breast Cancer CellsJournal of Medicinal Chemistry, 2008
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized studyBiotherapy, 1993